Georg R. Hess
Mainz, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 98 publications
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2026
Treatment intensification does not improve outcomes beyond rituximab-based therapy in primary mediastinal B-cell lymphoma: a multicenter retrospective analysis.
Journal: Leukemia & lymphoma
Published: June 10, 2026
Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.
Journal: Haematologica
Published: April 12, 2026
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.
Journal: Lancet (London, England)
Published: February 19, 2026
Disseminated Strongyloides stercoralis Infection Diagnosed by Metagenomic Next-Generation Sequencing of a Cell-Free DNA blood sample in a Patient with Hematologic Malignancy in Germany: A Case Report.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: February 01, 2026
Disseminated Strongyloides stercoralis infection diagnosed by metagenomic next-generation sequencing of a cell-free DNA blood sample in a patient with hematologic malignancy in Germany: A case report.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: February 01, 2026
Healthcare resource utilization analysis in newly diagnosed mantle cell lymphoma: resource alleviation with adoption of the TRIANGLE ibrutinib regimen without autologous stem cell transplantation.
Journal: Annals of hematology
Published: January 27, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Journal: Lancet (London, England)
Published: December 23, 2025
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
Journal: American journal of hematology
Published: November 21, 2025
Austrian Real-world Experience With Standard of Care Brexucabtagene Autoleucel in Patients With Relapsed or Refractory Mantle-Cell Lymphoma.
Journal: Transplantation and cellular therapy
Published: August 26, 2025
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland.
Journal: Bone marrow transplantation
Published: July 27, 2025
Last Updated: 09/26/2026